Open Access

HOW I DO IT

The Rezum system – a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia

Christopher H. Cantrill¹, Kevin C. Zorn², Dean S. Elterman³, Ricardo R. Gonzalez⁴

1 Urology San Antonio, San Antonio, Texas, USA
2 Department of Urology, University of Montreal Hospital Center, Montreal, Quebec, Canada
3 Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada
4 Houston Methodist Hospital, Houston, Texas, USA
Address correspondence to Dr. Ricardo R. Gonzalez, Houston Methodist Hospital, 6560 Fannin Street, Suite 2100, Houston, TX 77030 USA

Canadian Journal of Urology 2019, 26(3), 9787-9793.

Abstract

Benign prostatic hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) sits in the top ten prominent and costly disease conditions in men over 50 years of age. In the United States it is the most common diagnosis made by urologists for men 45 to 74 years of age. Twenty percent of the population will reach 65 years of age or older by 2030, and those over 85 years will represent the fastest growing segment of our population. The prevalence of symptomatic BPH increases proportionally with the aging population. It is estimated that BPH now affects 6% of the male population worldwide. Moreover, in Canada, the estimated BPH prevalence is more than 1 million men aged 50 years and older. Among the various surgical treatments, Rezum water vapor thermal therapy has been developed as a unique, rapid and reproducible minimally invasive surgical treatment exhibiting safe and early effective relief of LUTS/BPH. The targeted prostate tissue ablation is amenable to all zones of the prostate including intravesical median lobes. We present our experiences with this technique, which can be quickly performed under local anesthesia in an office setting.

---

Keywords

---